Prostate Cancer Treatment and Research

The paper identifies chromatin pre-accessibility and FOXA1-mediated repression as key regulators of GR action in prostate cancer, offering new strategies to combat antiandrogen resistance.

This study identifies 5hmC-based gene set activity scores in cfDNA as biomarkers for early detection of ADT resistance in prostate cancer.

The paper identifies 14 metastasis-related mutated genes and develops a Mscore to predict metastatic risk in primary prostate tumors using xgboost.

curatedPCaData harmonizes prostate cancer datasets to enable meta-analysis and clinical insights across multiple cohorts.

The paper identifies an intermediate basal cell population (Basal-B) in the prostate that shows lineage plasticity and contributes to both homeostasis and cancer initiation.

The paper identifies a novel RNA-based mechanism in prostate cancer where BAZ2A interacts with TOP2A and KDM1A to repress gene expression, distinct from its role in rRNA gene silencing.

This study investigates the antitumour activity of CT7001, a CDK7 inhibitor, in castration-resistant prostate cancer models, showing it inhibits proliferation and enhances enzalutamide efficacy.

This study identifies biomarkers and trajectories of prostate cancer progression using bioinformatics fusion of weighted correlation network analysis and machine learning, finding the EZH2-TROAP axis as a key trajectory and 58 validated biomarkers.

This study identifies differentially expressed genes in prostate epithelial stem and transit amplifying cells from prostate cancer and benign prostate hyperplasia patients, finding USP10 and SOCS3 associated with prostate cancer.

This study investigates Thio-2's mechanism of action in inhibiting AR signaling in CRPC, showing it acts independently of BAG-1 isoforms and with potential AR NTD binding.

This study identifies multi-omics prognostic signatures for prostate cancer using transcriptomics and metabolomics data, showing their ability to stratify patients into distinct risk groups.

This study identifies distinct structural variation patterns in prostate cancer across disease states, defining clinically actionable subgroups based on whole genome profiling.

The paper uses scRNAseq and pharmacogenomics to identify FK866 as a potential drug for aggressive prostate cancer, showing its efficacy against drug-resistant and stem-like cells.

The paper identifies a gene signature associated with citrate and spermine secretion in prostate epithelial cells and shows its expression decreases in aggressive prostate cancer.

This study shows MYC overexpression disrupts AR transcriptional pause release, promoting aggressive prostate cancer progression.

The paper identifies transcriptional network disruptions in drug-resistant prostate cancer using TraRe, uncovering key regulatory modules and transcription factors associated with resistance.

The paper compares the chromatin binding and transcriptional activities of AR and AR-V7 in prostate cancer cells, finding distinct cistromes and transcriptomes.

This study uses patient-derived organoids to investigate drug sensitivity in multifocal prostate cancer and develops a transcriptomics-based model to predict drug responses.

The paper identifies key molecules and signaling pathways in AZIN1-regulated prostate cancer using RNA-seq data from the GSE189379 dataset.

The paper reports genomic analyses of prostate cancer cell lines, identifying mutations and chromothripsis events associated with TP53 inactivation.

This paper introduces a biologically informed deep learning model for prostate cancer classification and identifies molecular drivers of treatment resistance.

This study shows BAZ2A's role in prostate cancer stem-like state transition through its interaction with H3K14ac and repression of tumor suppressor genes.

PCaDB provides a database for analyzing transcriptomes from prostate cancer cohorts and includes scRNA-seq data and prognostic signatures to aid in diagnosis and prognosis.

The paper re-analyzes scRNA-seq datasets to show that luminal progenitor clusters across studies overlap and matches FACS-enriched LSCmed cells in mice and humans.

This study identifies transcriptional states in mCRPC that mediate treatment resistance, including AR splicing heterogeneity, TGF-β signaling, and immune infiltration patterns.

The paper quantifies the abundance and interactome of the TMPRSS2-ERG fusion protein in prostate cancer cells using IP-MS assays, identifying key isoforms and interaction partners.

This study identifies RUNX1 as a marker for a castration-resistant luminal lineage in the developing and adult mouse prostate, distinct from NKX3.1+ cells.